Full Press Release Details
WOBURN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences:
Leerink Partners 2026 Global Healthcare ConferenceDate: Monday, March 9, 2026Fireside Chat Time: 2:20 pm EDT
Jefferies 2026 Biotech on the Beach SummitDate: Tuesday, March 10, 20261x1 Meetings
Live webcasts of the fireside chat will be available in the Investors section of Replimune’s website atwww.replimune.com. A replay will be available for 30 days following the conference.
About ReplimuneReplimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is intended to ignite local activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to then activate a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visitwww.replimune.com.